<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Down syndrome: Clinical features and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Down syndrome: Clinical features and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Down syndrome: Clinical features and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn K Ostermaier, MD, FAAP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jan E Drutz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Down syndrome (DS) is the most common chromosome abnormality among liveborn infants. It is the most frequent form of intellectual disability caused by a microscopically demonstrable chromosomal aberration. DS is characterized by a variety of dysmorphic features, congenital malformations, and other health problems and medical conditions. Not all of them are present in each affected person. The impact of DS for each person is individual, with some persons being profoundly impacted while others are healthy and able to live independently as adults. In general, persons with DS are now reaching fuller potentials secondary to better educational programs, medical advancements, community resources, and the support of family and friends.</p><p>The clinical features and diagnosis of DS will be presented here. The epidemiology, genetics, and management are discussed separately. (See  <a class="medical medical_review" href="/d/html/426.html" rel="external">"Down syndrome: Overview of prenatal screening"</a> and  <a class="medical medical_review" href="/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities", section on 'Trisomy 21 (Down syndrome)'</a> and  <a class="medical medical_review" href="/d/html/2938.html" rel="external">"Down syndrome: Management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DYSMORPHIC FEATURES</span><span class="headingEndMark"> — </span>Upslanting palpebral fissures, epicanthic folds, and brachycephaly are nearly universal features of DS. The other characteristic dysmorphic features of DS are each present in 47 to 82 percent of cases [<a href="#rid1">1,2</a>]. These features predominantly affect the head and neck and the extremities.</p><p class="headingAnchor" id="H3"><span class="h2">Head and neck</span><span class="headingEndMark"> — </span>Characteristic dysmorphic features of DS affecting the head and neck include:</p><p class="bulletIndent1"><span class="glyph">●</span>Upslanting palpebral fissures</p><p class="bulletIndent1"><span class="glyph">●</span>Epicanthic folds  (<a class="graphic graphic_picture graphicRef64030" href="/d/graphic/64030.html" rel="external">picture 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Flat facial profile/flat nasal bridge</p><p class="bulletIndent1"><span class="glyph">●</span>Folded or dysplastic ears</p><p class="bulletIndent1"><span class="glyph">●</span>Low-set small ears</p><p class="bulletIndent1"><span class="glyph">●</span>Brachycephaly</p><p class="bulletIndent1"><span class="glyph">●</span>Brushfield spots</p><p class="bulletIndent1"><span class="glyph">●</span>Open mouth</p><p class="bulletIndent1"><span class="glyph">●</span>Protruding tongue  (<a class="graphic graphic_picture graphicRef64030" href="/d/graphic/64030.html" rel="external">picture 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Furrowed tongue</p><p class="bulletIndent1"><span class="glyph">●</span>Short neck</p><p class="bulletIndent1"><span class="glyph">●</span>Excessive skin at nape of the neck</p><p class="bulletIndent1"><span class="glyph">●</span>Narrow palate</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal teeth</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Extremities</span><span class="headingEndMark"> — </span>Characteristic dysmorphic features of DS affecting the extremities include:</p><p class="bulletIndent1"><span class="glyph">●</span>Short broad hands</p><p class="bulletIndent1"><span class="glyph">●</span>Incurved fifth finger with hypoplastic middle phalanx</p><p class="bulletIndent1"><span class="glyph">●</span>Transverse palmar crease  (<a class="graphic graphic_picture graphicRef79414" href="/d/graphic/79414.html" rel="external">picture 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Space between the first and second toes (sandal gap)</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperflexibility of joints</p><p></p><p class="headingAnchor" id="H12589040"><span class="h2">Neonatal features</span><span class="headingEndMark"> — </span>Ten of the characteristic dysmorphic features are common in newborns with DS and are usually recognized soon after birth. In a series of 48 affected newborns, all had four or more features, and 89 percent had six or more [<a href="#rid1">1,3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Flat facial profile</p><p class="bulletIndent1"><span class="glyph">●</span>Slanted palpebral fissures</p><p class="bulletIndent1"><span class="glyph">●</span>Anomalous ears</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotonia  (<a class="graphic graphic_picture graphicRef68246" href="/d/graphic/68246.html" rel="external">picture 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Poor Moro reflex</p><p class="bulletIndent1"><span class="glyph">●</span>Dysplasia of middle phalanx of fifth finger</p><p class="bulletIndent1"><span class="glyph">●</span>Transverse palmar (Simian) crease  (<a class="graphic graphic_picture graphicRef79414" href="/d/graphic/79414.html" rel="external">picture 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Excessive skin at nape of the neck</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperflexibility of joints</p><p class="bulletIndent1"><span class="glyph">●</span>Dysplasia of pelvis</p><p></p><p class="headingAnchor" id="H2051182724"><span class="h1">NEUROPSYCHIATRIC DISORDERS</span></p><p class="headingAnchor" id="H6"><span class="h2">Intellectual disability</span><span class="headingEndMark"> — </span>Almost all individuals with DS have cognitive impairment, although the range is wide. Most are mildly to moderately intellectually disabled, with an intelligence quotient (IQ) in the 50 to 70 or 35 to 50 range, respectively, although some are severely impaired with an IQ of 20 to 35 [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/6172.html" rel="external">"Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis"</a>.)</p><p>Developmental impairment becomes apparent in the first year of life. In general, the average age of sitting (11 months), creeping (17 months), and walking (26 months) is approximately twice the typical age [<a href="#rid5">5</a>]. The sequence of language development is the same, although the rate is slower, with the average age for the first word at 18 months [<a href="#rid6">6</a>]. The child with DS continues to learn new skills. However, IQ declines through the first 10 years of age, reaching a plateau in adolescence that continues into adulthood [<a href="#rid2">2,7,8</a>]. (See  <a class="medical medical_review" href="/d/html/615.html" rel="external">"Developmental-behavioral surveillance and screening in primary care", section on 'Approach to surveillance'</a>.)</p><p>The profile of cognitive impairment in DS appears to differ from other forms of intellectual disability. The cognitive deficits are primarily in morphosyntax, verbal short-term memory, and explicit long-term memory [<a href="#rid9">9</a>]. The most common profile, in which language comprehension is equal to mental age and language production is more delayed, occurs in two-thirds of affected children [<a href="#rid10">10</a>]. In one-third, language comprehension, mental age, and language production are equal. Impairment in expressive language was noted in another study of children with DS, who had fewer different and total words and decreased mean length of utterance compared with controls matched for nonverbal mental age [<a href="#rid11">11</a>]. Vocabulary skills accelerated more rapidly than syntax (average sentence length and structure) and surpassed mental age in adolescence. Similar findings of increasing differences in comprehension with age were noted in another report, in which children with DS developed relatively stronger skills in vocabulary compared with syntax [<a href="#rid12">12</a>]. Other selective deficits have been described, such as greater difficulty understanding sequences or grammatical rules [<a href="#rid2">2,13</a>].</p><p class="headingAnchor" id="H2688065"><span class="h2">Behavioral and psychiatric disorders</span><span class="headingEndMark"> — </span>Behavioral and psychiatric disorders are more common in DS than typical children but less common than in those with other causes of intellectual disability [<a href="#rid8">8</a>]. In one report, psychiatric disorders affected 17.6 percent of individuals with DS less than 20 years of age [<a href="#rid14">14</a>]. Disruptive behavioral disorders, such as attention-deficit hyperactivity disorder, conduct/oppositional disorder, or aggressive behavior, were most common. In the same study, psychiatric disorders, most often consisting of major depressive illness or aggressive behavior, affected 25.6 percent of DS adults. (See  <a class="medical medical_review" href="/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/1232.html" rel="external">"Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1224.html" rel="external">"Pediatric unipolar depression: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p>Autism is a common comorbidity of DS, affecting as many as 7 percent of children with DS [<a href="#rid15">15</a>]. The diagnosis is often delayed compared with children without DS [<a href="#rid16">16</a>]. Some children with DS present in the school-aged years with new-onset or worsening autistic-like features, cognitive decline to the point of dementia, and new-onset insomnia [<a href="#rid17">17</a>]. The term "Down syndrome disintegrative disorder" has been suggested to describe this cluster of clinical findings, although it is not clear if this is one disorder or several different ones with similar presentations. The etiology is not known, but autoimmunity is suspected. There are no established diagnosis or treatment recommendations for this clinical association. Some patients respond to psychiatric care. Further research is needed in this area. (See  <a class="medical medical_review" href="/d/html/627.html" rel="external">"Autism spectrum disorder in children and adolescents: Clinical features"</a>.)</p><p class="headingAnchor" id="H1726646571"><span class="h2">Dementia/Alzheimer disease</span><span class="headingEndMark"> — </span>Adults with DS usually develop neuropathologic and functional changes typical of Alzheimer disease by the sixth decade of life [<a href="#rid8">8,18,19</a>]. In one report, dementia was present in 49 of 96 (51 percent) DS individuals over the age of 35 years [<a href="#rid18">18</a>]. The average age of onset was 54 years, and seizures developed in 84 percent of patients. In another report, over 75 percent of patients over 65 years of age were affected [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">CARDIOVASCULAR DISEASE</span><span class="headingEndMark"> — </span>Approximately one-half of individuals with DS have congenital heart disease [<a href="#rid20">20-22</a>]. In the largest population-based study, cardiovascular abnormalities were identified in 342 of 821 (42 percent) infants born with DS from 1985 to 2006 in the northeast region of England [<a href="#rid22">22</a>]. Twenty-three percent had more than one anomaly. The secondary lesion was most commonly an atrial septal defect (ASD) or patent ductus arteriosus (PDA). The following primary lesions were identified:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete atrioventricular septal defect (CAVSD) – 37 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Ventricular septal defect (VSD) – 31 percent</p><p class="bulletIndent1"><span class="glyph">●</span>ASD – 15 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Partial atrioventricular septal defect (PAVSD) – 6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Tetralogy of Fallot (TOF) – 5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>PDA – 4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Miscellaneous – 2 percent</p><p></p><p>The clinical features of these defects are discussed separately. (See  <a class="medical medical_review" href="/d/html/5754.html" rel="external">"Isolated atrial septal defects (ASDs) in children: Classification, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5787.html" rel="external">"Isolated ventricular septal defects (VSDs) in infants and children: Anatomy, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1421.html" rel="external">"Clinical manifestations and diagnosis of patent ductus arteriosus (PDA) in term infants, children, and adults"</a> and  <a class="medical medical_review" href="/d/html/5769.html" rel="external">"Tetralogy of Fallot (TOF): Pathophysiology, clinical features, and diagnosis"</a>.)</p><p>Some asymptomatic adolescents and adults without structural heart disease develop valve abnormalities [<a href="#rid23">23,24</a>]. In a series of 35 patients with DS, mitral valve prolapse occurred in 46 percent and aortic regurgitation in 6 percent at an average age of 20 years [<a href="#rid23">23</a>]. In another report of 30 adults, mitral valve regurgitation occurred in 17 percent [<a href="#rid24">24</a>].</p><p>Pulmonary hypertension is also common, occurring in 28 percent of patients with DS in one retrospective review [<a href="#rid25">25</a>]. The median age at diagnosis was five days in this review, with the majority (70 percent) having transient disease that lasted a median of eight months. Recurrent disease occurred in 15 percent and was associated with congenital heart disease, obstructive sleep apnea, recurrent pneumonia, and intermittent hypoxia. The remaining 15 percent had persistent disease. (See <a class="local">'Pulmonary disorders'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h1">GASTROINTESTINAL ABNORMALITIES</span><span class="headingEndMark"> — </span>Children with trisomy 21 are at increased risk for gastrointestinal tract anomalies, which occur in approximately 5 percent of cases [<a href="#rid26">26</a>]. Duodenal atresia or stenosis, sometimes associated with annular pancreas, is the most characteristic lesion, occurring in 2.5 percent [<a href="#rid2">2</a>]. Imperforate anus and esophageal atresia with tracheoesophageal fistula are seen less often. Conversely, DS affects 28 percent of patients with duodenal atresia or stenosis and 20 percent with annular pancreas. (See  <a class="medical medical_review" href="/d/html/5863.html" rel="external">"Intestinal atresia"</a> and  <a class="medical medical_review" href="/d/html/5635.html" rel="external">"Annular pancreas"</a> and  <a class="medical medical_review" href="/d/html/14208.html" rel="external">"Prenatal diagnosis of esophageal, gastrointestinal, and anorectal atresia"</a> and  <a class="medical medical_review" href="/d/html/6377.html" rel="external">"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula", section on 'Tracheoesophageal fistula and esophageal atresia'</a>.)</p><p>Hirschsprung disease is more common in DS than in the general population, although the risk is less than 1 percent [<a href="#rid4">4</a>]. Among children with Hirschsprung disease, approximately 2 percent have trisomy 21 (with a range of 2 to 15 percent) [<a href="#rid27">27-31</a>]. (See  <a class="medical medical_review" href="/d/html/5903.html" rel="external">"Congenital aganglionic megacolon (Hirschsprung disease)"</a>.)</p><p>A strong association appears to exist between DS and celiac disease. The prevalence of biopsy-proven celiac disease has been reported to be between 5 and 16 percent, representing a 5- to 16-fold increase compared with the general population [<a href="#rid32">32-36</a>]. (See  <a class="medical medical_review" href="/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'High-risk groups'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">GROWTH</span><span class="headingEndMark"> — </span>Birth weight, length, and head circumference are less in DS compared with typical infants. Newborns with DS weigh approximately 0.18 to 0.37 kg less than their siblings [<a href="#rid37">37</a>]. Mean length at birth is approximately 0.5 standard deviations less than control newborns [<a href="#rid38">38</a>]. In a study of 105 children with DS, growth parameters remained lower until puberty, with the growth spurt being earlier (age 11 in males and 9.5 in females), and were blunted compared with controls [<a href="#rid39">39</a>]. Weight gain during the first three years of life has improved since the 1980s, as has stature in males [<a href="#rid40">40-42</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Short stature</span><span class="headingEndMark"> — </span>Growth rate is reduced in DS compared with typical children, especially in infancy and adolescence. Growth is most reduced in children with severe congenital heart disease [<a href="#rid38">38,40</a>]. In adults with DS, the average height in males and females was 61.7 and 57 inches (157 and 144 cm), respectively, and the average weight was 157 and 140 lb (71 and 64 kg) in males and females in a 1998 study [<a href="#rid43">43</a>]. Measurement of growth in patients with DS is discussed separately. (See  <a class="medical medical_review" href="/d/html/2938.html" rel="external">"Down syndrome: Management", section on 'Growth'</a>.)</p><p>The cause of DS-associated growth retardation remains unknown. Low circulating levels of insulin-like growth factor 1 (IGF-1) and diminished provoked and spontaneous secretion of growth hormone (GH) have been reported in some patients [<a href="#rid44">44,45</a>]. Serum GH levels are not low in children with DS [<a href="#rid46">46,47</a>], but suboptimal endogenous GH production as a result of hypothalamic dysfunction has been demonstrated [<a href="#rid48">48</a>]. Selective deficiency of IGF-1, but not IGF-2, has been seen in DS patients who are older than two years [<a href="#rid49">49,50</a>]. IGF-1 receptors are present in brain cells from fetuses with trisomy 21 [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Obesity</span><span class="headingEndMark"> — </span>The prevalence of obesity (defined as a body mass index [BMI] &gt;27.8 kg/m<sup>2</sup> in adult males and &gt;27.3 kg/m<sup>2</sup> in adult females) is greater in DS than in the general population (45 versus 33 percent, 56 versus 36 percent, for males and females, respectively) [<a href="#rid43">43</a>]. This is thought to result from the reduced resting metabolic rate in children and adults with DS [<a href="#rid51">51,52</a>]. In general, weight is less than expected for length in infants with DS and then increases disproportionally so that the majority of children are obese by age three to four years [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/2938.html" rel="external">"Down syndrome: Management", section on 'Obesity prevention'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">EYE PROBLEMS</span><span class="headingEndMark"> — </span>Ophthalmologic disorders that require monitoring and intervention affect the majority of children with DS. Disorders that are the most common include [<a href="#rid8">8,53-57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Refractive errors (myopia, hyperopia, astigmatism) – 35 to 76 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Strabismus – 25 to 57 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Nystagmus – 18 to 22 percent</p><p></p><p>Cataracts occur in 5 percent of newborns. Starting in the second decade of life, many individuals develop corneal opacities. Children occasionally develop glaucoma. (See  <a class="medical medical_review" href="/d/html/6272.html" rel="external">"Overview of glaucoma in infants and children"</a> and  <a class="medical medical_review" href="/d/html/6270.html" rel="external">"Cataract in children", section on 'Clinical features'</a>.)</p><p>The frequency of ocular disorders increases with age. In one report, eye abnormalities occurred in 38 percent of infants 2 to 12 months of age and 80 percent of children age 5 to 12 years [<a href="#rid53">53</a>]. These abnormalities may be more prevalent in adults. In one report of 30 institutionalized adults with DS, only one had nearly normal ocular status [<a href="#rid58">58</a>]. Nine had keratoconus, an abnormal shape or thinning of the cornea that impairs visual acuity.</p><p class="headingAnchor" id="H13"><span class="h1">HEARING LOSS</span><span class="headingEndMark"> — </span>Hearing impairment affects 38 to 78 percent of individuals with DS [<a href="#rid8">8,59,60</a>]. Otitis media is a frequent problem, affecting 50 to 70 percent of DS children, and it is often the cause of hearing loss in this population [<a href="#rid4">4</a>]. Monitoring for this condition is important to preserve hearing. Congenital hearing loss is also more common in DS, identified in 15 percent of newborns with DS compared with 0.25 percent in the total neonate population in one retrospective review [<a href="#rid61">61</a>].</p><p>The characteristics of hearing loss were illustrated by a study of 47 children with DS, 2 months to 3.5 years of age, evaluated by auditory brainstem response testing [<a href="#rid60">60</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>The loss was unilateral or bilateral in 28 and 38 percent, respectively; 34 percent of patients had normal hearing.</p><p class="bulletIndent1"><span class="glyph">●</span>The loss was conductive in 19 ears, sensorineural in 16, and mixed in 14.</p><p class="bulletIndent1"><span class="glyph">●</span>The extent of loss was mild, moderate, and severe to profound in 33, 13, and 3 ears, respectively.</p><p></p><p>Another series of 332 children with DS born in Utah found that [<a href="#rid62">62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Forty-six percent had hearing loss, 32 percent of whom were identified on newborn screening and the rest in later infancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most newborns and infants had conductive hearing loss due to serous otitis media and required placement of tympanostomy tubes, although a few children were identified with sensorineural or mixed hearing loss, primarily identified by newborn screening.</p><p></p><p class="headingAnchor" id="H2688495"><span class="h1">ENDOCRINE DISORDERS</span><span class="headingEndMark"> — </span>Endocrine abnormalities in DS include thyroid dysfunction and diabetes.</p><p class="headingAnchor" id="H2688520"><span class="h2">Thyroid disease</span><span class="headingEndMark"> — </span>Thyroid disorders are common in DS. The prevalence varies, depending in part upon the population studied and the age of testing. The prevalence of hypothyroidism ranged from 3 to 54 percent in reports of adults with DS [<a href="#rid63">63</a>]. Hyperthyroidism is also relatively common, occurring in 2.5 percent of institutionalized adults [<a href="#rid64">64</a>].</p><p>Thyroid disease is also frequently seen in children with DS, as indicated in the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span>In a longitudinal study of 85 DS patients up to 25 years of age, 35 percent had hypothyroidism. One-half developed the disorder before age eight years [<a href="#rid63">63</a>]. Two percent had hyperthyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 320 children with DS aged five days to 10 years, 28 percent had abnormal thyroid function tests [<a href="#rid65">65</a>]. Of these, diagnoses included primary congenital hypothyroidism in 6, acquired hypothyroidism in 1, transient hyperthyrotropinemia in 2, compensated hypothyroidism (T4 concentration normal or close to the lower limit of normal and increased thyroid-stimulating hormone [TSH] level) in 16, and mild compensated hypothyroidism (mildly elevated TSH concentration) in 65. None had hyperthyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective cohort study of 122 infants less than four months of age with DS, 17.5 percent had primary hypothyroidism that required therapy, and 15 percent had compensated hypothyroidism [<a href="#rid66">66</a>].</p><p></p><p>However, there is a shift in thyroid hormone levels in patients with DS who have no overt symptoms of thyroid disease, suggesting that normal values may be different in this group. In a large cohort from a neonatal screening program, T4 concentrations in newborns with DS had a normal distribution but were shifted to lower concentrations than the general population [<a href="#rid67">67</a>]. Mean TSH concentration was significantly increased (9.76 versus 3.96 milli-international units/L), and T4-binding globulin was normal compared with controls. The distribution plots for TSH and free T4 were shifted to higher values in another study of patients with DS (median age 10, range six months to 64 years) [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H2688527"><span class="h2">Diabetes</span><span class="headingEndMark"> — </span>The risk of type 1 diabetes appears to be increased in DS [<a href="#rid36">36,69-71</a>]. Data from a Dutch study in children up to 14 years of age suggest the risk of type 1 diabetes is three times greater in DS than in the general population (50 versus 12.4 per 100,000 per year) [<a href="#rid70">70,71</a>]. In another study, the estimated prevalence of type 1 diabetes in DS children up to nine years of age was eight times greater than the age-matched control population (335 versus 40 per 100,000) [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H14"><span class="h1">HEMATOLOGIC DISORDERS</span><span class="headingEndMark"> — </span>Hematologic abnormalities affecting red blood cells, white blood cells, and platelets are common in DS, particularly during childhood. The lifetime risk of leukemia in DS is 1 to 1.5 percent [<a href="#rid72">72,73</a>].</p><p>Approximately 65 percent of newborns with trisomy 21 have polycythemia [<a href="#rid74">74</a>]. In one report, plasma erythropoietin concentration measured in umbilical cord blood was higher in infants with DS compared with controls, suggesting that chronic fetal hypoxemia may explain the high incidence of polycythemia [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/5940.html" rel="external">"Neonatal polycythemia"</a>.)</p><p>Children with DS often have macrocytosis [<a href="#rid74">74,76</a>]. In one study, mean corpuscular volume (MCV) was greater in DS children age two to six years compared with controls (86.9 versus 80.6 fL), and MCV &gt;95<sup>th</sup> percentile for age was more likely to occur (66 versus 11 percent) [<a href="#rid76">76</a>]. Hematocrits were higher in the DS patients (39.1 versus 36.9 percent), although all were normal for age. (See  <a class="medical medical_review" href="/d/html/7166.html" rel="external">"Macrocytosis/Macrocytic anemia"</a>.)</p><p>White blood cell counts are decreased in DS [<a href="#rid74">74,76</a>]. In the study cited above, white blood cell counts &lt;5<sup>th</sup> percentile for age occurred more often in DS than controls (33 versus 6 percent) [<a href="#rid76">76</a>]. The macrocytosis and leukopenia were not explained by folate deficiency, because serum and red blood cell folate concentrations were similar between the patients and controls. Thrombocytosis is common in infancy, and thrombocytopenia is rare [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Transient myeloproliferative disorder</span><span class="headingEndMark"> — </span>Transient myeloproliferative disorder (TMD), also known as transient leukemia or transient abnormal myelopoiesis (TAM), is a form of leukemia that almost exclusively affects newborns with DS. It is typically detected on routine screening with a complete blood count (identification of blasts on the peripheral smear). The majority of newborns are asymptomatic, with spontaneous resolution of the disorder by two to three months (median 54 days), although some develop severe disease including hydrops fetalis, hyperleukocytosis, liver failure, and cardiopulmonary failure. TMD is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/16914.html" rel="external">"Transient abnormal myelopoiesis (TAM) of Down syndrome (DS)"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Acute megakaryoblastic leukemia</span><span class="headingEndMark"> — </span>In prospective and retrospective studies, up to 26 percent of infants with transient leukemia later developed the French-American-British (FAB) classification system M7 subtype of acute myeloid leukemia (AML-M7), also known as acute megakaryoblastic leukemia (AMKL) or myeloid leukemia of DS (ML-DS) [<a href="#rid77">77-79</a>]. AMKL occurs in approximately 1 in 50 to 200 children with DS. The incidence is approximately 500 times greater in children with than without DS. (See  <a class="medical medical_review" href="/d/html/86098.html" rel="external">"Acute myeloid leukemia: Classification"</a>.)</p><p>AMKL develops during the first four years of life. It is most commonly seen by two years of age and is invariably associated with variants in guanine-adenine-thymine-adenine (GATA) binding factor 1 gene (<em>GATA1</em>) [<a href="#rid73">73,78,80-85</a>]. In contrast, myeloid leukemias in people with DS aged four years or older are usually negative for <em>GATA1</em> variants, and their prognosis does not differ from AML in patients without DS. Many affected patients (20 to 69 percent) present with myelodysplastic syndrome, consisting of progressive thrombocytopenia followed by anemia [<a href="#rid72">72</a>]. Some develop hepatomegaly and liver failure due to fibrosis [<a href="#rid86">86</a>]. Neutropenia and infection rarely are seen [<a href="#rid86">86</a>]. Treatment issues are complex as children with DS and either acute lymphoblastic leukemia (ALL) or AMKL are subject to high initial rates of treatment-related mortality [<a href="#rid87">87</a>].</p><p>There is evidence that these <em>GATA1</em> variants are acquired in utero and that finding such variants at birth might serve as a biomarker for an increased risk of transient leukemia and subsequent AMKL [<a href="#rid88">88,89</a>]. In one study, three of four children with DS and AMKL had the same <em>GATA1</em> variant in a neonatal blood spot (Guthrie card) that was found at the time of clinical diagnosis of AMKL 12 to 26 months later [<a href="#rid90">90</a>].</p><p>Gene expression profiling may help in distinguishing transient leukemia from AMKL [<a href="#rid91">91</a>] and identifying those at risk of progressing from transient leukemia to AMKL [<a href="#rid92">92</a>], as well as distinguishing the AMKL seen in children with DS from AMKL seen in those without DS [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Acute lymphoblastic leukemia</span><span class="headingEndMark"> — </span>The risk of developing ALL is approximately 10 to 20 times higher in DS compared with children without DS [<a href="#rid36">36,94-96</a>] and accounts for 1 to 3 percent of all patients with ALL. The clinical presentation is similar to that in children without DS. (See  <a class="medical medical_review" href="/d/html/6244.html" rel="external">"Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children"</a>.)</p><p>In a report comparing ALL in children with and without DS, the following findings were noted at presentation [<a href="#rid72">72,94</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Leukocyte count and leukemic cell mass were similar.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age distribution and immunophenotype were similar.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinically, they were indistinguishable [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mediastinal mass (1.6 versus 8.9 percent) and central nervous system (CNS) leukemia (0 versus 2.7 percent) were less common in DS, both favorable prognostic signs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Less T cell leukemia or translocation of (9;22) or t(4;11) were seen in DS, both unfavorable prognostic signs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytogenetic differences occurred, including less hyperdiploidy in DS, an unfavorable prognostic sign.</p><p></p><p>Children with DS who develop ALL often respond to chemotherapy, similar to children without DS. The treatment and outcome for children with DS and ALL are discussed separately. (See  <a class="medical medical_review" href="/d/html/6247.html" rel="external">"Acute lymphoblastic leukemia/lymphoblastic lymphoma: Outcomes and late effects of treatment in children and adolescents"</a>.)</p><p class="headingAnchor" id="H5936278"><span class="h1">PULMONARY DISORDERS</span><span class="headingEndMark"> — </span>Sixty percent of 208 children with DS in a 2004 survey were reported by their parents to have respiratory conditions, including sleep apnea and asthma [<a href="#rid97">97</a>], although this may be an underestimate based upon results from other studies [<a href="#rid98">98</a>]. Other pulmonary complications that are more common in children with DS include disorders of the pulmonary vasculature, parenchymal lung disease, upper and lower airway abnormalities, and chronic aspiration [<a href="#rid99">99</a>]. Respiratory tract infections are also more frequent and often more severe than in children without DS.</p><p class="headingAnchor" id="H2688733"><span class="h2">Sleep apnea</span><span class="headingEndMark"> — </span>Obstructive sleep apnea (OSA) occurs in at least 30 to 75 percent of children with DS, including those who are not obese [<a href="#rid98">98,100-106</a>]. In a population of 65 unselected 3.5 year olds with DS, polysomnograms were classified as abnormal with evidence of OSA in 57 percent. Among the 45 children whose parents reported no sleep problems, 54 percent had abnormal results [<a href="#rid98">98</a>]. The mechanism includes soft tissue and skeletal alterations that lead to upper airway obstruction. In infants with DS, OSA was associated with dysphagia, gastrointestinal conditions such as gastroesophageal reflux disease, and congenital heart disease [<a href="#rid106">106</a>]. Intermittent hypoxemia may lead to pulmonary hypertension and contribute to mental impairment [<a href="#rid107">107</a>]. (See  <a class="medical medical_review" href="/d/html/6347.html" rel="external">"Mechanisms and predisposing factors for sleep-related breathing disorders in children"</a>.)</p><p class="headingAnchor" id="H2688998"><span class="h1">SKIN DISORDERS</span><span class="headingEndMark"> — </span>The majority of DS children have associated skin disorders, which are considered benign [<a href="#rid108">108-110</a>]. In one series, 62 of 71 children (87 percent) had skin abnormalities in the following proportions [<a href="#rid111">111</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Palmoplantar hyperkeratosis – 41 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Seborrheic dermatitis – 31 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Fissured tongue – 20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cutis marmorata – 13 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Geographic tongue – 11 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Xerosis – 10 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Alopecia areata – 8 percent [<a href="#rid108">108,109</a>]</p><p></p><p>In adolescents, dermatologic problems become particularly bothersome. The most common condition in this age group is folliculitis, which affects 50 to 60 percent of patients [<a href="#rid112">112</a>].</p><p class="headingAnchor" id="H22"><span class="h1">REPRODUCTION</span><span class="headingEndMark"> — </span>Females with DS are fertile and may become pregnant. In one series, 30 pregnancies in 26 women resulted in 10 offspring with DS, 18 (including one set of twins) without DS, and 3 spontaneous abortions [<a href="#rid113">113</a>]. Appropriate counseling should be provided for management of menstruation and contraception [<a href="#rid114">114</a>].</p><p>Nearly all males with DS are infertile. The mechanism is impairment of spermatogenesis [<a href="#rid115">115</a>]. However, cases have been reported of offspring from fathers with DS [<a href="#rid116">116,117</a>].</p><p class="headingAnchor" id="H12592131"><span class="h1">UROLOGIC ABNORMALITIES</span><span class="headingEndMark"> — </span>Studies suggest an increased incidence of urologic abnormalities in individuals with DS. These include hypospadias (1 in 250 males), cryptorchidism (14 to 27 percent of males), testicular cancer, and kidney malformations (3.5 percent) [<a href="#rid118">118</a>]. (See  <a class="medical medical_review" href="/d/html/6583.html" rel="external">"Hypospadias: Pathogenesis, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/d/html/2850.html" rel="external">"Undescended testes (cryptorchidism) in children: Clinical features and evaluation"</a> and  <a class="medical medical_review" href="/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors"</a> and  <a class="medical medical_review" href="/d/html/6110.html" rel="external">"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">ATLANTOAXIAL INSTABILITY</span><span class="headingEndMark"> — </span>Atlantoaxial instability (AAI), defined as excessive mobility of the articulation of the atlas (C1) and the axis (C2), may lead to subluxation of the cervical spine [<a href="#rid119">119</a>]. Approximately 13 percent of individuals with DS have asymptomatic AAI, while spinal cord compression due to the disorder affects approximately 2 percent [<a href="#rid120">120</a>]. The diagnosis is made by lateral neck radiographs taken in neutral position, flexion, and extension. (See  <a class="medical medical_review" href="/d/html/2938.html" rel="external">"Down syndrome: Management", section on 'Atlantoaxial instability'</a>.)</p><p>Patients with symptomatic spinal cord compression may have neck pain, torticollis, gait abnormalities, loss of bowel or bladder control, or signs of quadriparesis or quadriplegia and require immediate stabilization. Asymptomatic individuals appear to remain asymptomatic whether or not physical activity is restricted [<a href="#rid121">121,122</a>]. In one study, DS children with AAI were randomly assigned to participate or not in athletic activities considered to be risky and evaluated after one year. The groups were similar in motor function, frequency of neurologic signs, and changes in atlantoaxial distance and were also similar to children with DS and without AAI [<a href="#rid121">121</a>].</p><p class="headingAnchor" id="H25"><span class="h1">ARTHROPATHY</span><span class="headingEndMark"> — </span>DS arthropathy has a prevalence of 8 to 10 per 1000, or approximately six times the prevalence of juvenile idiopathic arthritis in the general population [<a href="#rid123">123</a>]. In a review of 30 cases, 17 had polyarticular disease at symptom onset, and 13 had oligoarticular disease at symptom onset, but 7 of these progressed to polyarticular disease. Average delay from symptom onset to diagnosis was two years.</p><p class="headingAnchor" id="H2689257"><span class="h1">IMMUNODEFICIENCY</span><span class="headingEndMark"> — </span>DS is associated with a variety of immunologic impairments that are thought to be related to the increased susceptibility to infection, autoimmune disorders, and malignancies [<a href="#rid124">124-128</a>]. Chemotactic defects [<a href="#rid129">129</a>], decreased immunoglobulin G4 (IgG4) levels [<a href="#rid130">130</a>], and quantitative and qualitative abnormalities of the T cell and B cell systems have been inconsistently demonstrated [<a href="#rid124">124-126,131</a>]. Whether these represent a primary immunodeficiency or early senescence of the immune system is uncertain.</p><p>Support for an intrinsic immunodeficiency is provided by a cross-sectional study in which immunophenotyping was used to evaluate lymphocyte subpopulations in 96 children with DS who ranged in age from 1 to 20 years [<a href="#rid132">132</a>]. In another study, children with DS had a diminished expansion of T and B cells in the first years of life compared with previously published data on healthy children without DS [<a href="#rid133">133</a>]. B cells remained diminished (with 88 percent of values below the 10<sup>th</sup> percentile), although T cells eventually approximated normal levels. Reduced naive mature and memory B cell numbers and evidence of impaired antigen selection for IgM+ and IgA+ memory B cells were seen in one small study [<a href="#rid134">134</a>].</p><p class="headingAnchor" id="H29"><span class="h1">DIAGNOSIS OF DOWN SYNDROME</span><span class="headingEndMark"> — </span>The diagnosis of DS is often made by prenatal screening. (See  <a class="medical medical_review" href="/d/html/422.html" rel="external">"First-trimester combined test and integrated tests for screening for Down syndrome and trisomy 18"</a> and  <a class="medical medical_review" href="/d/html/414.html" rel="external">"Maternal serum marker screening for Down syndrome: Levels and laboratory issues"</a>.)</p><p>When no prenatal diagnosis is available, DS is usually recognized from the characteristic phenotypic features present in the newborn (see <a class="local">'Dysmorphic features'</a> above). Diagnosis should be confirmed with a genetic test (eg, a karyotype performed on a blood sample). Alternative methods (eg, interphase fluorescent in situ hybridization [FISH] for trisomy 21 or quantitative fluorescence-polymerase chain reaction [QF-PCR]) may be used to expedite diagnosis, but these investigations should always be followed by a full karyotype in order to detect DS due to translocations (eg, Robertsonian translocations involving chromosome 21) or mosaic DS.</p><p class="headingAnchor" id="H3150003864"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110061.html" rel="external">"Society guideline links: Down syndrome"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15529.html" rel="external">"Patient education: Down syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/1193.html" rel="external">"Patient education: Down syndrome (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12588736"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of Down syndrome (DS) is often made by prenatal screening. DS is otherwise usually recognized from the characteristic phenotypic features present in the newborn. A clinical diagnosis of DS should be confirmed by genetic testing whenever possible. (See <a class="local">'Diagnosis of Down syndrome'</a> above and  <a class="medical medical_review" href="/d/html/422.html" rel="external">"First-trimester combined test and integrated tests for screening for Down syndrome and trisomy 18"</a> and  <a class="medical medical_review" href="/d/html/414.html" rel="external">"Maternal serum marker screening for Down syndrome: Levels and laboratory issues"</a> and <a class="local">'Neonatal features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysmorphic features </strong>– The characteristic dysmorphic features of DS predominantly affect the head and neck and the extremities  (<a class="graphic graphic_picture graphicRef64030" href="/d/graphic/64030.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef79414" href="/d/graphic/79414.html" rel="external">picture 2</a>). Ten of the characteristic dysmorphic features are common in newborns with DS and are usually recognized soon after birth. (See <a class="local">'Dysmorphic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropsychiatric disorders</strong> – Almost all persons with DS have cognitive impairment, although the range is wide. Most are mildly to moderately intellectually disabled, although some are severely impaired. Behavioral and psychiatric disorders are more common in DS than typical children but less common than in those with other causes of intellectual disability. (See <a class="local">'Neuropsychiatric disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular disease</strong> – Approximately one-half of persons with DS have congenital heart disease. Septal defects are the most common. Some asymptomatic adolescents and adults without structural heart disease develop valve abnormalities. (See <a class="local">'Cardiovascular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal abnormalities</strong> – Children with trisomy 21 are at increased risk for gastrointestinal tract anomalies, including duodenal atresia or stenosis, imperforate anus, and esophageal atresia with tracheoesophageal fistula. They are also at increased risk for celiac disease and Hirschsprung disease. (See <a class="local">'Gastrointestinal abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth</strong> – Birth weight, length, and head circumference are less in DS compared with typical infants. The growth rate for height is reduced in DS compared with typical children. In general, weight is less than expected for length in infants with DS and then increases disproportionally so that the majority of children are obese by age three to four years. (See <a class="local">'Growth'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye and hearing problems</strong> – Ophthalmologic disorders are common in patients with DS and increase in frequency with age. These disorders include refractive errors, strabismus, nystagmus, cataracts, and keratoconus. Hearing loss is also common, and otitis media is a frequent problem. (See <a class="local">'Eye problems'</a> above and <a class="local">'Hearing loss'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine disorders</strong> – Endocrine abnormalities in DS include thyroid dysfunction and type 1 diabetes. (See <a class="local">'Endocrine disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fertility and reproduction –</strong> Females with DS are fertile and may become pregnant. However, nearly all males with DS are infertile. (See <a class="local">'Reproduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atlantoaxial instability </strong>– Persons with DS are at increased risk of atlantoaxial instability (AAI), defined as excessive mobility of the articulation of the atlas (C1) and the axis (C2), although spinal cord compression due to subluxation of the cervical spine is uncommon. (See <a class="local">'Atlantoaxial instability'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematologic abnormalities</strong> – Hematologic abnormalities affecting red cells, white cells, and platelets are common in DS and include polycythemia, macrocytosis, leukopenia, thrombocytosis, and leukemia (transient, acute megakaryoblastic, and acute lymphoblastic). (See <a class="local">'Hematologic disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunologic abnormalities</strong> – DS is associated with a variety of immunologic impairments that are thought to be related to the increased susceptibility to infection, autoimmune disorders, and malignancies. However, these defects are inconsistently demonstrated. Whether these represent a primary immunodeficiency or early senescence of the immune system is uncertain. (See <a class="local">'Immunodeficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other abnormalities</strong> – Increased rates of urologic abnormalities, arthropathy, pulmonary disease, and benign skin disorders are also seen in patients with DS. (See <a class="local">'Urologic abnormalities'</a> above and <a class="local">'Arthropathy'</a> above and <a class="local">'Pulmonary disorders'</a> above and <a class="local">'Skin disorders'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Jones KL. Down syndrome. In: Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.7.</li><li class="breakAll">Epstein CJ. Down syndrome (Trisomy 21). In: The metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1223.</li><li><a class="nounderline abstract_t">Hall B. Mongolism in newborn infants. An examination of the criteria for recognition and some speculations on the pathogenic activity of the chromosomal abnormality. Clin Pediatr (Phila) 1966; 5:4.</a></li><li><a class="nounderline abstract_t">Bull MJ, Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics 2011; 128:393.</a></li><li class="breakAll">Winders PC. Gross motor milestone statistics. In: Gross motor skills in children with Down syndrome: A guide for parents and professionals, Woodbine House, Baltimore 1997. p.228.</li><li><a class="nounderline abstract_t">Kumin L. Speech and language skills in children with Down syndrome. MRDD Research Reviews 1996; 2:109.</a></li><li><a class="nounderline abstract_t">Brown FR 3rd, Greer MK, Aylward EH, Hunt HH. Intellectual and adaptive functioning in individuals with Down syndrome in relation to age and environmental placement. Pediatrics 1990; 85:450.</a></li><li><a class="nounderline abstract_t">Roizen NJ, Patterson D. Down's syndrome. Lancet 2003; 361:1281.</a></li><li><a class="nounderline abstract_t">Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol 2010; 9:623.</a></li><li class="breakAll">Miller JF. Profiles of language development in children with Down syndrome. In: Improving the communication of people with Down syndrome, Miller JF, Leddy M, Leavitt LA (Eds), Brookes, Baltimore 1999. p.11.</li><li><a class="nounderline abstract_t">Chapman RS, Seung HK, Schwartz SE, Kay-Raining Bird E. Language skills of children and adolescents with Down syndrome: II. Production deficits. J Speech Lang Hear Res 1998; 41:861.</a></li><li><a class="nounderline abstract_t">Chapman RS, Schwartz SE, Bird EK. Language skills of children and adolescents with Down syndrome: I. Comprehension. J Speech Hear Res 1991; 34:1106.</a></li><li><a class="nounderline abstract_t">Kernan KT. Comprehension of syntactically indicated sequence by Down's syndrome and other mentally retarded adults. J Ment Defic Res 1990; 34 ( Pt 2):169.</a></li><li><a class="nounderline abstract_t">Myers BA, Pueschel SM. Psychiatric disorders in persons with Down syndrome. J Nerv Ment Dis 1991; 179:609.</a></li><li><a class="nounderline abstract_t">Kent L, Evans J, Paul M, Sharp M. Comorbidity of autistic spectrum disorders in children with Down syndrome. Dev Med Child Neurol 1999; 41:153.</a></li><li><a class="nounderline abstract_t">Rasmussen P, Börjesson O, Wentz E, Gillberg C. Autistic disorders in Down syndrome: background factors and clinical correlates. Dev Med Child Neurol 2001; 43:750.</a></li><li><a class="nounderline abstract_t">Worley G, Crissman BG, Cadogan E, et al. Down Syndrome Disintegrative Disorder: New-Onset Autistic Regression, Dementia, and Insomnia in Older Children and Adolescents With Down Syndrome. J Child Neurol 2015; 30:1147.</a></li><li><a class="nounderline abstract_t">Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989; 46:849.</a></li><li><a class="nounderline abstract_t">Visser FE, Aldenkamp AP, van Huffelen AC, et al. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am J Ment Retard 1997; 101:400.</a></li><li><a class="nounderline abstract_t">Freeman SB, Taft LF, Dooley KJ, et al. Population-based study of congenital heart defects in Down syndrome. Am J Med Genet 1998; 80:213.</a></li><li><a class="nounderline abstract_t">Dennis J, Archer N, Ellis J, Marder L. Recognising heart disease in children with Down syndrome. Arch Dis Child Educ Pract Ed 2010; 95:98.</a></li><li><a class="nounderline abstract_t">Irving CA, Chaudhari MP. Cardiovascular abnormalities in Down's syndrome: spectrum, management and survival over 22 years. Arch Dis Child 2012; 97:326.</a></li><li><a class="nounderline abstract_t">Geggel RL, O'Brien JE, Feingold M. Development of valve dysfunction in adolescents and young adults with Down syndrome and no known congenital heart disease. J Pediatr 1993; 122:821.</a></li><li><a class="nounderline abstract_t">Hamada T, Gejyo F, Koshino Y, et al. Echocardiographic evaluation of cardiac valvular abnormalities in adults with Down's syndrome. Tohoku J Exp Med 1998; 185:31.</a></li><li><a class="nounderline abstract_t">Bush D, Galambos C, Ivy DD, et al. Clinical Characteristics and Risk Factors for Developing Pulmonary Hypertension in Children with Down Syndrome. J Pediatr 2018; 202:212.</a></li><li><a class="nounderline abstract_t">Fabia J, Drolette M. Malformations and leukemia in children with Down's syndrome. Pediatrics 1970; 45:60.</a></li><li><a class="nounderline abstract_t">Moore SW, Johnson AG. Hirschsprung's disease: genetic and functional associations of Down's and Waardenburg syndromes. Semin Pediatr Surg 1998; 7:156.</a></li><li><a class="nounderline abstract_t">Sarioglu A, Tanyel FC, Büyükpamukçu N, Hiçsönmez A. Hirschsprung-associated congenital anomalies. Eur J Pediatr Surg 1997; 7:331.</a></li><li><a class="nounderline abstract_t">Menezes M, Puri P. Long-term clinical outcome in patients with Hirschsprung's disease and associated Down's syndrome. J Pediatr Surg 2005; 40:810.</a></li><li><a class="nounderline abstract_t">Garver KL, Law JC, Garver B. Hirschsprung disease: a genetic study. Clin Genet 1985; 28:503.</a></li><li><a class="nounderline abstract_t">Ikeda K, Goto S. Additional anomalies in Hirschsprung's disease: an analysis based on the nationwide survey in Japan. Z Kinderchir 1986; 41:279.</a></li><li><a class="nounderline abstract_t">Carlsson AK, Axelsson IE, Borulf SK, et al. Serological screening for celiac disease in healthy 2.5-year-old children in Sweden. Pediatrics 2001; 107:42.</a></li><li><a class="nounderline abstract_t">Book L, Hart A, Black J, et al. Prevalence and clinical characteristics of celiac disease in Downs syndrome in a US study. Am J Med Genet 2001; 98:70.</a></li><li><a class="nounderline abstract_t">Zachor DA, Mroczek-Musulman E, Brown P. Prevalence of celiac disease in Down syndrome in the United States. J Pediatr Gastroenterol Nutr 2000; 31:275.</a></li><li><a class="nounderline abstract_t">Mäki M, Mustalahti K, Kokkonen J, et al. Prevalence of Celiac disease among children in Finland. N Engl J Med 2003; 348:2517.</a></li><li><a class="nounderline abstract_t">Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Cancers and immune related diseases associated with Down's syndrome: a record linkage study. Arch Dis Child 2004; 89:1014.</a></li><li><a class="nounderline abstract_t">Pueschel SM, Rothman KJ, Ogilby JD. Birth weight of children with Down's syndrome. Am J Ment Defic 1976; 80:442.</a></li><li><a class="nounderline abstract_t">Cronk CE. Growth of children with Down's syndrome: birth to age 3 years. Pediatrics 1978; 61:564.</a></li><li><a class="nounderline abstract_t">Toledo C, Alembik Y, Aguirre Jaime A, Stoll C. Growth curves of children with Down syndrome. Ann Genet 1999; 42:81.</a></li><li><a class="nounderline abstract_t">Cronk C, Crocker AC, Pueschel SM, et al. Growth charts for children with Down syndrome: 1 month to 18 years of age. Pediatrics 1988; 81:102.</a></li><li><a class="nounderline abstract_t">Zemel BS, Pipan M, Stallings VA, et al. Growth Charts for Children With Down Syndrome in the United States. Pediatrics 2015; 136:e1204.</a></li><li><a class="nounderline abstract_t">Styles ME, Cole TJ, Dennis J, Preece MA. New cross sectional stature, weight, and head circumference references for Down's syndrome in the UK and Republic of Ireland. Arch Dis Child 2002; 87:104.</a></li><li><a class="nounderline abstract_t">Rubin SS, Rimmer JH, Chicoine B, et al. Overweight prevalence in persons with Down syndrome. Ment Retard 1998; 36:175.</a></li><li><a class="nounderline abstract_t">Annerén G, Gustavson KH, Sara VR, Tuvemo T. Growth retardation in Down syndrome in relation to insulin-like growth factors and growth hormone. Am J Med Genet Suppl 1990; 7:59.</a></li><li><a class="nounderline abstract_t">Torrado C, Bastian W, Wisniewski KE, Castells S. Treatment of children with Down syndrome and growth retardation with recombinant human growth hormone. J Pediatr 1991; 119:478.</a></li><li><a class="nounderline abstract_t">Milunsky A, Lowy C, Rubenstein AH, Wright AD. Carbohydrate tolerance, growth hormone and insulin levels in mongolism. Dev Med Child Neurol 1968; 10:25.</a></li><li><a class="nounderline abstract_t">Annerén G, Sara VR, Hall K, Tuvemo T. Growth and somatomedin responses to growth hormone in Down's syndrome. Arch Dis Child 1986; 61:48.</a></li><li><a class="nounderline abstract_t">Castells S, Beaulieu I, Torrado C, et al. Hypothalamic versus pituitary dysfunction in Down's syndrome as cause of growth retardation. J Intellect Disabil Res 1996; 40 ( Pt 6):509.</a></li><li><a class="nounderline abstract_t">Sara VR, Gustavson KH, Annerén G, et al. Somatomedins in Down's syndrome. Biol Psychiatry 1983; 18:803.</a></li><li><a class="nounderline abstract_t">Sara VR, Sjögren B, Annerén G, et al. The presence of normal receptors for somatomedin and insulin in fetuses with Down's syndrome. Biol Psychiatry 1984; 19:591.</a></li><li><a class="nounderline abstract_t">Allison DB, Gomez JE, Heshka S, et al. Decreased resting metabolic rate among persons with Down Syndrome. Int J Obes Relat Metab Disord 1995; 19:858.</a></li><li><a class="nounderline abstract_t">Luke A, Roizen NJ, Sutton M, Schoeller DA. Energy expenditure in children with Down syndrome: correcting metabolic rate for movement. J Pediatr 1994; 125:829.</a></li><li><a class="nounderline abstract_t">Roizen NJ, Mets MB, Blondis TA. Ophthalmic disorders in children with Down syndrome. Dev Med Child Neurol 1994; 36:594.</a></li><li><a class="nounderline abstract_t">Shapiro MB, France TD. The ocular features of Down's syndrome. Am J Ophthalmol 1985; 99:659.</a></li><li><a class="nounderline abstract_t">Caputo AR, Wagner RS, Reynolds DR, et al. Down syndrome. Clinical review of ocular features. Clin Pediatr (Phila) 1989; 28:355.</a></li><li><a class="nounderline abstract_t">Kim JH, Hwang JM, Kim HJ, Yu YS. Characteristic ocular findings in Asian children with Down syndrome. Eye (Lond) 2002; 16:710.</a></li><li><a class="nounderline abstract_t">Creavin AL, Brown RD. Ophthalmic abnormalities in children with Down syndrome. J Pediatr Ophthalmol Strabismus 2009; 46:76.</a></li><li><a class="nounderline abstract_t">Hestnes A, Sand T, Fostad K. Ocular findings in Down's syndrome. J Ment Defic Res 1991; 35 ( Pt 3):194.</a></li><li><a class="nounderline abstract_t">Shott SR, Joseph A, Heithaus D. Hearing loss in children with Down syndrome. Int J Pediatr Otorhinolaryngol 2001; 61:199.</a></li><li><a class="nounderline abstract_t">Roizen NJ, Wolters C, Nicol T, Blondis TA. Hearing loss in children with Down syndrome. J Pediatr 1993; 123:S9.</a></li><li><a class="nounderline abstract_t">Tedeschi AS, Roizen NJ, Taylor HG, et al. The prevalence of congenital hearing loss in neonates with Down syndrome. J Pediatr 2015; 166:168.</a></li><li><a class="nounderline abstract_t">Park AH, Wilson MA, Stevens PT, et al. Identification of hearing loss in pediatric patients with Down syndrome. Otolaryngol Head Neck Surg 2012; 146:135.</a></li><li><a class="nounderline abstract_t">Karlsson B, Gustafsson J, Hedov G, et al. Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity. Arch Dis Child 1998; 79:242.</a></li><li><a class="nounderline abstract_t">Sare Z, Ruvalcaba RH, Kelley VC. Prevalence of thyroid disorder in Down syndrome. Clin Genet 1978; 14:154.</a></li><li><a class="nounderline abstract_t">Tüysüz B, Beker DB. Thyroid dysfunction in children with Down's syndrome. Acta Paediatr 2001; 90:1389.</a></li><li><a class="nounderline abstract_t">Purdy IB, Singh N, Brown WL, et al. Revisiting early hypothyroidism screening in infants with Down syndrome. J Perinatol 2014; 34:936.</a></li><li><a class="nounderline abstract_t">van Trotsenburg AS, Vulsma T, van Santen HM, et al. Lower neonatal screening thyroxine concentrations in down syndrome newborns. J Clin Endocrinol Metab 2003; 88:1512.</a></li><li><a class="nounderline abstract_t">Meyerovitch J, Antebi F, Greenberg-Dotan S, et al. Hyperthyrotropinaemia in untreated subjects with Down's syndrome aged 6 months to 64 years: a comparative analysis. Arch Dis Child 2012; 97:595.</a></li><li><a class="nounderline abstract_t">Anwar AJ, Walker JD, Frier BM. Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications. Diabet Med 1998; 15:160.</a></li><li><a class="nounderline abstract_t">Van Goor JC, Massa GG, Hirasing R. Increased incidence and prevalence of diabetes mellitus in Down's syndrome. Arch Dis Child 1997; 77:186.</a></li><li><a class="nounderline abstract_t">Ruwaard D, Hirasing RA, Reeser HM, et al. Increasing incidence of type I diabetes in The Netherlands. The second nationwide study among children under 20 years of age. Diabetes Care 1994; 17:599.</a></li><li><a class="nounderline abstract_t">Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000; 110:512.</a></li><li><a class="nounderline abstract_t">Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009; 113:2619.</a></li><li><a class="nounderline abstract_t">Kivivuori SM, Rajantie J, Siimes MA. Peripheral blood cell counts in infants with Down's syndrome. Clin Genet 1996; 49:15.</a></li><li><a class="nounderline abstract_t">Widness JA, Pueschel SM, Pezzullo JC, Clemons GK. Elevated erythropoietin levels in cord blood of newborns with Down's syndrome. Biol Neonate 1994; 66:50.</a></li><li><a class="nounderline abstract_t">Roizen NJ, Amarose AP. Hematologic abnormalities in children with Down syndrome. Am J Med Genet 1993; 46:510.</a></li><li><a class="nounderline abstract_t">Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006; 107:4606.</a></li><li><a class="nounderline abstract_t">Zipursky A. Transient leukaemia--a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 2003; 120:930.</a></li><li><a class="nounderline abstract_t">Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down's syndrome: a review. Pediatr Hematol Oncol 1987; 4:211.</a></li><li><a class="nounderline abstract_t">Shivdasani RA. Molecular and transcriptional regulation of megakaryocyte differentiation. Stem Cells 2001; 19:397.</a></li><li><a class="nounderline abstract_t">Izraeli S. Leukaemia -- a developmental perspective. Br J Haematol 2004; 126:3.</a></li><li><a class="nounderline abstract_t">Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5:11.</a></li><li><a class="nounderline abstract_t">Mundschau G, Gurbuxani S, Gamis AS, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 2003; 101:4298.</a></li><li><a class="nounderline abstract_t">Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003; 101:4301.</a></li><li><a class="nounderline abstract_t">Alford KA, Reinhardt K, Garnett C, et al. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood 2011; 118:2222.</a></li><li><a class="nounderline abstract_t">Zipursky A, Rose T, Skidmore M, et al. Hydrops fetalis and neonatal leukemia in Down syndrome. Pediatr Hematol Oncol 1996; 13:81.</a></li><li><a class="nounderline abstract_t">Rao A, Hills RK, Stiller C, et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2006; 132:576.</a></li><li><a class="nounderline abstract_t">Taub JW, Mundschau G, Ge Y, et al. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood 2004; 104:1588.</a></li><li><a class="nounderline abstract_t">Pine SR, Guo Q, Yin C, et al. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood 2007; 110:2128.</a></li><li><a class="nounderline abstract_t">Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004; 103:2480.</a></li><li><a class="nounderline abstract_t">McElwaine S, Mulligan C, Groet J, et al. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol 2004; 125:729.</a></li><li><a class="nounderline abstract_t">Kanezaki R, Toki T, Terui K, et al. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood 2010; 116:4631.</a></li><li><a class="nounderline abstract_t">Bourquin JP, Subramanian A, Langebrake C, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A 2006; 103:3339.</a></li><li><a class="nounderline abstract_t">Dördelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group. Leukemia 1998; 12:645.</a></li><li><a class="nounderline abstract_t">Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355:165.</a></li><li><a class="nounderline abstract_t">Whitlock JA. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 2006; 135:595.</a></li><li><a class="nounderline abstract_t">Thomas K, Bourke J, Girdler S, et al. Variation over time in medical conditions and health service utilization of children with Down syndrome. J Pediatr 2011; 158:194.</a></li><li><a class="nounderline abstract_t">Shott SR, Amin R, Chini B, et al. Obstructive sleep apnea: Should all children with Down syndrome be tested? Arch Otolaryngol Head Neck Surg 2006; 132:432.</a></li><li><a class="nounderline abstract_t">McDowell KM, Craven DI. Pulmonary complications of Down syndrome during childhood. J Pediatr 2011; 158:319.</a></li><li><a class="nounderline abstract_t">Marcus CL, Keens TG, Bautista DB, et al. Obstructive sleep apnea in children with Down syndrome. Pediatrics 1991; 88:132.</a></li><li><a class="nounderline abstract_t">Stebbens VA, Dennis J, Samuels MP, et al. Sleep related upper airway obstruction in a cohort with Down's syndrome. Arch Dis Child 1991; 66:1333.</a></li><li><a class="nounderline abstract_t">Southall DP, Stebbens VA, Mirza R, et al. Upper airway obstruction with hypoxaemia and sleep disruption in Down syndrome. Dev Med Child Neurol 1987; 29:734.</a></li><li><a class="nounderline abstract_t">Levanon A, Tarasiuk A, Tal A. Sleep characteristics in children with Down syndrome. J Pediatr 1999; 134:755.</a></li><li><a class="nounderline abstract_t">Dyken ME, Lin-Dyken DC, Poulton S, et al. Prospective polysomnographic analysis of obstructive sleep apnea in down syndrome. Arch Pediatr Adolesc Med 2003; 157:655.</a></li><li><a class="nounderline abstract_t">Fitzgerald DA, Paul A, Richmond C. Severity of obstructive apnoea in children with Down syndrome who snore. Arch Dis Child 2007; 92:423.</a></li><li><a class="nounderline abstract_t">Goffinski A, Stanley MA, Shepherd N, et al. Obstructive sleep apnea in young infants with Down syndrome evaluated in a Down syndrome specialty clinic. Am J Med Genet A 2015; 167A:324.</a></li><li><a class="nounderline abstract_t">Breslin J, Spanò G, Bootzin R, et al. Obstructive sleep apnea syndrome and cognition in Down syndrome. Dev Med Child Neurol 2014; 56:657.</a></li><li><a class="nounderline abstract_t">Barankin B, Guenther L. Dermatological manifestations of Down's syndrome. J Cutan Med Surg 2001; 5:289.</a></li><li><a class="nounderline abstract_t">Madan V, Williams J, Lear JT. Dermatological manifestations of Down's syndrome. Clin Exp Dermatol 2006; 31:623.</a></li><li><a class="nounderline abstract_t">Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 children with Down syndrome. Pediatr Dermatol 2007; 24:317.</a></li><li><a class="nounderline abstract_t">Ercis M, Balci S, Atakan N. Dermatological manifestations of 71 Down syndrome children admitted to a clinical genetics unit. Clin Genet 1996; 50:317.</a></li><li><a class="nounderline abstract_t">Pueschel SM. Clinical aspects of Down syndrome from infancy to adulthood. Am J Med Genet Suppl 1990; 7:52.</a></li><li><a class="nounderline abstract_t">Bovicelli L, Orsini LF, Rizzo N, et al. Reproduction in Down syndrome. Obstet Gynecol 1982; 59:13S.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics. Committee on Genetics. American Academy of Pediatrics: Health supervision for children with Down syndrome. Pediatrics 2001; 107:442.</a></li><li><a class="nounderline abstract_t">Johannisson R, Gropp A, Winking H, et al. Down's syndrome in the male. Reproductive pathology and meiotic studies. Hum Genet 1983; 63:132.</a></li><li><a class="nounderline abstract_t">Zühlke C, Thies U, Braulke I, et al. Down syndrome and male fertility: PCR-derived fingerprinting, serological and andrological investigations. Clin Genet 1994; 46:324.</a></li><li><a class="nounderline abstract_t">Sheridan R, Llerena J Jr, Matkins S, et al. Fertility in a male with trisomy 21. J Med Genet 1989; 26:294.</a></li><li><a class="nounderline abstract_t">Mercer ES, Broecker B, Smith EA, et al. Urological manifestations of Down syndrome. J Urol 2004; 171:1250.</a></li><li><a class="nounderline abstract_t">Cohen WI. Atlantoaxial instability. What's next? Arch Pediatr Adolesc Med 1998; 152:119.</a></li><li><a class="nounderline abstract_t">Pueschel SM, Scola FH. Atlantoaxial instability in individuals with Down syndrome: epidemiologic, radiographic, and clinical studies. Pediatrics 1987; 80:555.</a></li><li><a class="nounderline abstract_t">Cremers MJ, Bol E, de Roos F, van Gijn J. Risk of sports activities in children with Down's syndrome and atlantoaxial instability. Lancet 1993; 342:511.</a></li><li><a class="nounderline abstract_t">Pueschel SM, Scola FH, Pezzullo JC. A longitudinal study of atlanto-dens relationships in asymptomatic individuals with Down syndrome. Pediatrics 1992; 89:1194.</a></li><li><a class="nounderline abstract_t">Juj H, Emery H. The arthropathy of Down syndrome: an underdiagnosed and under-recognized condition. J Pediatr 2009; 154:234.</a></li><li><a class="nounderline abstract_t">Ugazio AG, Maccario R, Notarangelo LD, Burgio GR. Immunology of Down syndrome: a review. Am J Med Genet Suppl 1990; 7:204.</a></li><li><a class="nounderline abstract_t">Nespoli L, Burgio GR, Ugazio AG, Maccario R. Immunological features of Down's syndrome: a review. J Intellect Disabil Res 1993; 37 ( Pt 6):543.</a></li><li><a class="nounderline abstract_t">Cuadrado E, Barrena MJ. Immune dysfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system? Clin Immunol Immunopathol 1996; 78:209.</a></li><li><a class="nounderline abstract_t">Bloemers BL, van Bleek GM, Kimpen JL, Bont L. Distinct abnormalities in the innate immune system of children with Down syndrome. J Pediatr 2010; 156:804.</a></li><li><a class="nounderline abstract_t">Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol 2011; 164:9.</a></li><li><a class="nounderline abstract_t">Novo E, García MI, Lavergne J. Nonspecific immunity in Down syndrome: a study of chemotaxis, phagocytosis, oxidative metabolism, and cell surface marker expression of polymorphonuclear cells. Am J Med Genet 1993; 46:384.</a></li><li><a class="nounderline abstract_t">Annerén G, Magnusson CG, Lilja G, Nordvall SL. Abnormal serum IgG subclass pattern in children with Down's syndrome. Arch Dis Child 1992; 67:628.</a></li><li><a class="nounderline abstract_t">Berman S, Lee B, Nuss R, et al. Immunoglobulin G, total and subclass, in children with or without recurrent otitis media. J Pediatr 1992; 121:249.</a></li><li><a class="nounderline abstract_t">de Hingh YC, van der Vossen PW, Gemen EF, et al. Intrinsic abnormalities of lymphocyte counts in children with down syndrome. J Pediatr 2005; 147:744.</a></li><li><a class="nounderline abstract_t">Comans-Bitter WM, de Groot R, van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997; 130:388.</a></li><li><a class="nounderline abstract_t">Verstegen RH, Driessen GJ, Bartol SJ, et al. Defective B-cell memory in patients with Down syndrome. J Allergy Clin Immunol 2014; 134:1346.</a></li></ol></div><div id="topicVersionRevision">Topic 2917 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Jones KL. Down syndrome. In: Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epstein CJ. Down syndrome (Trisomy 21). In: The metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1223.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4221291" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mongolism in newborn infants. An examination of the criteria for recognition and some speculations on the pathogenic activity of the chromosomal abnormality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21788214" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Health supervision for children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21788214" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Health supervision for children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Speech and language skills in children with Down syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137583" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Intellectual and adaptive functioning in individuals with Down syndrome in relation to age and environmental placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12699967" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20494326" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cognitive deficits and associated neurological complications in individuals with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20494326" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cognitive deficits and associated neurological complications in individuals with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9712133" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Language skills of children and adolescents with Down syndrome: II. Production deficits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1836243" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Language skills of children and adolescents with Down syndrome: I. Comprehension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2140415" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comprehension of syntactically indicated sequence by Down's syndrome and other mentally retarded adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1833506" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Psychiatric disorders in persons with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10210247" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comorbidity of autistic spectrum disorders in children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11730149" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Autistic disorders in Down syndrome: background factors and clinical correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25367918" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Down Syndrome Disintegrative Disorder: New-Onset Autistic Regression, Dementia, and Insomnia in Older Children and Adolescents With Down Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2527024" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A prospective study of Alzheimer disease in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9017086" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9843040" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Population-based study of congenital heart defects in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688855" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recognising heart disease in children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21835834" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cardiovascular abnormalities in Down's syndrome: spectrum, management and survival over 22 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8496770" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Development of valve dysfunction in adolescents and young adults with Down syndrome and no known congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9710943" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Echocardiographic evaluation of cardiac valvular abnormalities in adults with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30025669" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical Characteristics and Risk Factors for Developing Pulmonary Hypertension in Children with Down Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4243491" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Malformations and leukemia in children with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9718653" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hirschsprung's disease: genetic and functional associations of Down's and Waardenburg syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9493983" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hirschsprung-associated congenital anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15937820" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term clinical outcome in patients with Hirschsprung's disease and associated Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2934185" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hirschsprung disease: a genetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2947399" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Additional anomalies in Hirschsprung's disease: an analysis based on the nationwide survey in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134432" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Serological screening for celiac disease in healthy 2.5-year-old children in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11426458" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prevalence and clinical characteristics of celiac disease in Downs syndrome in a US study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10997372" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prevalence of celiac disease in Down syndrome in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12815137" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prevalence of Celiac disease among children in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15499053" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cancers and immune related diseases associated with Down's syndrome: a record linkage study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/129007" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Birth weight of children with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/149290" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Growth of children with Down's syndrome: birth to age 3 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10434121" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Growth curves of children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2962062" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Growth charts for children with Down syndrome: 1 month to 18 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26504127" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Growth Charts for Children With Down Syndrome in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12138054" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : New cross sectional stature, weight, and head circumference references for Down's syndrome in the UK and Republic of Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9638037" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Overweight prevalence in persons with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1963538" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Growth retardation in Down syndrome in relation to insulin-like growth factors and growth hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1831841" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment of children with Down syndrome and growth retardation with recombinant human growth hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4230643" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Carbohydrate tolerance, growth hormone and insulin levels in mongolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2937371" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Growth and somatomedin responses to growth hormone in Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9004111" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hypothalamic versus pituitary dysfunction in Down's syndrome as cause of growth retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6225471" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Somatomedins in Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6329329" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The presence of normal receptors for somatomedin and insulin in fetuses with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8963352" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Decreased resting metabolic rate among persons with Down Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7965444" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Energy expenditure in children with Down syndrome: correcting metabolic rate for movement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8034121" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ophthalmic disorders in children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3160242" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The ocular features of Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2527102" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Down syndrome. Clinical review of ocular features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12439664" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Characteristic ocular findings in Asian children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19343968" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ophthalmic abnormalities in children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1833550" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Ocular findings in Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11700189" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hearing loss in children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320600" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hearing loss in children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25444523" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The prevalence of congenital hearing loss in neonates with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21987652" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Identification of hearing loss in pediatric patients with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9875020" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/151610" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prevalence of thyroid disorder in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11853334" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Thyroid dysfunction in children with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24945161" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Revisiting early hypothyroidism screening in infants with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679431" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Lower neonatal screening thyroxine concentrations in down syndrome newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22535238" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hyperthyrotropinaemia in untreated subjects with Down's syndrome aged 6 months to 64 years: a comparative analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9507919" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9301372" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Increased incidence and prevalence of diabetes mellitus in Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8082532" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Increasing incidence of type I diabetes in The Netherlands. The second nationwide study among children under 20 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10997960" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The management of neoplastic disorders of haematopoiesis in children with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139078" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8721566" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Peripheral blood cell counts in infants with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7948440" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Elevated erythropoietin levels in cord blood of newborns with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8322810" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hematologic abnormalities in children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16469874" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12648061" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Transient leukaemia--a benign form of leukaemia in newborn infants with trisomy 21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2978961" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Megakaryoblastic leukemia and Down's syndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11553848" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Molecular and transcriptional regulation of megakaryocyte differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15198727" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Leukaemia -- a developmental perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15630411" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Origins of leukaemia in children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12560215" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12586620" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21715302" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8718505" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Hydrops fetalis and neonatal leukemia in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16445830" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15317736" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17576817" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14656875" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Natural history of GATA1 mutations in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180862" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20729467" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16492768" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593260" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10675114" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Risks of leukaemia and solid tumours in individuals with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054672" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Down syndrome and acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20934710" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Variation over time in medical conditions and health service utilization of children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16618913" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Obstructive sleep apnea: Should all children with Down syndrome be tested?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846671" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pulmonary complications of Down syndrome during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1829151" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Obstructive sleep apnea in children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1836718" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Sleep related upper airway obstruction in a cohort with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2961643" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Upper airway obstruction with hypoxaemia and sleep disruption in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10356146" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Sleep characteristics in children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860786" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Prospective polysomnographic analysis of obstructive sleep apnea in down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17449523" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Severity of obstructive apnoea in children with Down syndrome who snore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25604659" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Obstructive sleep apnea in young infants with Down syndrome evaluated in a Down syndrome specialty clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24471822" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Obstructive sleep apnea syndrome and cognition in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11907837" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Dermatological manifestations of Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901300" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Dermatological manifestations of Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17542890" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Mucocutaneous findings in 100 children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9007317" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Dermatological manifestations of 71 Down syndrome children admitted to a clinical genetics unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2149974" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Clinical aspects of Down syndrome from infancy to adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6211644" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Reproduction in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158488" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : American Academy of Pediatrics: Health supervision for children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6220959" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Down's syndrome in the male. Reproductive pathology and meiotic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7834902" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Down syndrome and male fertility: PCR-derived fingerprinting, serological and andrological investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2567354" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Fertility in a male with trisomy 21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767322" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Urological manifestations of Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9491035" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Atlantoaxial instability. What's next?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2958770" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Atlantoaxial instability in individuals with Down syndrome: epidemiologic, radiographic, and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8102665" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Risk of sports activities in children with Down's syndrome and atlantoaxial instability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1534403" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A longitudinal study of atlanto-dens relationships in asymptomatic individuals with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18783795" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : The arthropathy of Down syndrome: an underdiagnosed and under-recognized condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2149949" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Immunology of Down syndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8124000" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Immunological features of Down's syndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8605695" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Immune dysfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20172534" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Distinct abnormalities in the innate immune system of children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21352207" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Infections and immunodeficiency in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7689298" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Nonspecific immunity in Down syndrome: a study of chemotaxis, phagocytosis, oxidative metabolism, and cell surface marker expression of polymorphonuclear cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1534650" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Abnormal serum IgG subclass pattern in children with Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1640291" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Immunoglobulin G, total and subclass, in children with or without recurrent otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16356423" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Intrinsic abnormalities of lymphocyte counts in children with down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9063413" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25159464" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Defective B-cell memory in patients with Down syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
